Patents Examined by Steven Pohnert
  • Patent number: 11643687
    Abstract: The present invention relates to a method, in particular an in vitro method, for identifying B cells, comprising analyzing the methylation status of at least one CpG position in the mammalian gene region for Low density lipoprotein receptor-related protein 5 (LRP5), wherein a demethylation or lack of methylation of said gene region is indicative for a B cell, when compared to a non-B cell. The analyses according to the invention can identify B cells on an epi-genetic level and distinguish them from all other cells in complex samples, such as, for example, other blood or immune cells. The present invention furthermore provides an improved method for quantifying B cells, in particular in complex samples. The method can be performed without a step of purifying and/or enriching cells, preferably in whole blood and/or non-trypsinized tissue. Further claimed are kits and specific primers and probes for identifying methylation.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: May 9, 2023
    Assignee: Precision for Medicine GmbH
    Inventor: Sven Olek
  • Patent number: 11634747
    Abstract: A method for preserving and processing fetal nucleic acids located within maternal plasma is disclosed, wherein a sample of maternal blood containing fetal nucleic acids is treated to reduce both cell lysis of the maternal blood cells and deoxyribonuclease (DNase) and ribonuclease (RNase) activity within the fetal nucleic acids. The treatment of the sample aids in increasing the amount of fetal nucleic acids that can be identified and tested while maintaining the structure and integrity of the fetal nucleic acids.
    Type: Grant
    Filed: January 19, 2010
    Date of Patent: April 25, 2023
    Assignee: STRECK LLC
    Inventors: M. Rohan Fernando, Kate Chao-Wei Chen
  • Patent number: 11519042
    Abstract: The subject matter of the present invention is a method for the diagnosis or prognosis, in vitro, of lung cancer, which includes a step of detecting at least one expression product of at least one HERV nucleic acid sequence, a method for use of said nucleic acid sequences, which have been isolated, as a molecular marker or molecular markers, and a kit including at least one binding partner specific for at least one of the expression products of the HERV nucleic acid sequences.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: December 6, 2022
    Assignee: BIOMERIEUX
    Inventors: Philippe Perot, François Mallet, Cécile Montgiraud, Nathalie Mugnier
  • Patent number: 11479813
    Abstract: This application provides methods, kits, probes and primers, that can be used to analyze environmental samples, such as water samples, soil samples, and air samples. The methods and kits can include positive controls, to provide confidence in test results.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: October 25, 2022
    Assignee: UVic Industry Partnerships Inc.
    Inventors: Caren Christiane Helbing, Nicholas Veldhoen
  • Patent number: 11473147
    Abstract: The subject matter of the present invention is a method for the diagnosis or prognosis, in vitro, of testicular cancer, which includes a step of detecting at least one expression product of at least one HERV nucleic acid sequence, the use of said nucleic acid sequences, which have been isolated, as a molecular marker or molecular markers, and a kit including at least one binding partner specific for at least one of the expression products of the HERV nucleic acid sequences.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: October 18, 2022
    Assignee: BIOMERIEUX
    Inventors: Philippe Perot, François Mallet, Nathalie Mugnier
  • Patent number: 11459605
    Abstract: The present invention relates to a method for the in vitro diagnosis or prognosis of prostate cancer, which includes a step of detecting at least one expression product of at least one HERV nucleic acid sequence, the use of said nucleic acid sequences, once isolated, as one or more molecular marker(s) and a kit comprising at least one specific binding partner of at least one of the expression products of the HERV nucleic acid sequences.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: October 4, 2022
    Assignees: BIOMERIEUX, HOSPICES CIVILS DE LYON
    Inventors: François Mallet, Nathalie Mugnier, Philippe Perot
  • Patent number: 11453920
    Abstract: The present invention relates to a method for the in vitro diagnosis or prognosis of ovarian cancer, which includes a step of detecting at least one expression product of at least one HERV nucleic acid sequence, the use of said nucleic acid sequences, once isolated, as one or more molecular marker(s) and a kit including at least one specific binding partner of at least one of the expression products of the HERV nucleic acid sequences.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: September 27, 2022
    Assignee: BIOMERIEUX
    Inventors: Philippe Perot, François Mallet, Nathalie Mugnier
  • Patent number: 11453916
    Abstract: The present invention relates to a method for in vitro diagnosis or prognosis of colon cancer, including a step of detecting at least one expression product of at least one HERV nucleic acid sequence, the use of said isolated nucleic acid sequences as a molecular marker/molecular markers, and a kit including at least one specific binding partner for at least one expression product of the HERV nucleic acid sequences.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: September 27, 2022
    Assignees: BIOMERIEUX, HOSPICES CIVILS DE LYON
    Inventors: François Mallet, Nathalie Mugnier, Philippe Perot
  • Patent number: 11421276
    Abstract: This invention provides methods and compositions for diagnosing ischemia, ischemia reference expression profiles, and methods for identifying compounds for treating or preventing ischemia.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: August 23, 2022
    Assignee: The Regents of the University of California
    Inventors: Huichun Xu, Frank R. Sharp
  • Patent number: 11377690
    Abstract: The subject of the invention is a method for making an in vitro prognosis of severity for a patient in septic shock, including the following steps: (i) the level of expression of the expression product of at least one gene chosen from the lilrb2 and lilrb1 genes is measured in vitro on the basis of a biological sample taken from the patient, (ii) the level of expression of the expression product of the at least one gene is compared with a control level of expression, of the expression product of the same gene, with a good prognosis of severity, in which a level of expression of the expression product of the at least one gene below the control level of expression indicates a poor prognosis of severity for the patient, and also a kit for implementing the method.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: July 5, 2022
    Assignees: BIOMERIEUX, HOSPICES CIVILS DE LYON
    Inventors: Marie-Angelique Cazalis, Maud Tournoud, Fabienne Venet, Alain Lepape, Guillaume Monneret
  • Patent number: 11351154
    Abstract: The present invention provides compositions and methods useful for diagnosing, treating, and monitoring alcohol dependence and disorders and susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: June 7, 2022
    Assignee: University of Virginia Patent Foundation
    Inventor: Bankole A. Johnson
  • Patent number: 11313002
    Abstract: Disclosed are methods utilizing specific amplification of Candida sp. target nucleic acid for detecting the presence or absence of Candida sp. in a sample. Also disclosed are corresponding oligomers, including amplification oligomers, capture probes and detection probes, and combinations thereof, as well as corresponding reaction mixtures and kits.
    Type: Grant
    Filed: March 19, 2021
    Date of Patent: April 26, 2022
    Assignee: GEN-PROBE INCORPORATED
    Inventors: Angela S. Hudson, Damon K. Getman, Alice Jiang, Barbara L. Eaton
  • Patent number: 11299739
    Abstract: The present disclosure relates to aptamers for temperature-dependent reversible inhibition of thermostable polymerase activity in order to improve sensitivity and specificity of various reactions and assays involving hot start polynucleotide synthesis. Methods for use of the aptamers and related compositions and kits are also provided.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: April 12, 2022
    Assignee: CEPHEID
    Inventors: Sergey G. Lokhov, Alexander A. Gall, Vera Baraznenok, Ekaterina V. Viazovkina, Irina Shishkina, David H. Persing
  • Patent number: 11180809
    Abstract: Provided herein are methods of predicting a likelihood of survival following treatment with AA and prednisone in a patient having CRPC.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: November 23, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Deborah Sokol Ricci, Weimin Li, Michael Gormley, Jayaprakash Karkera, Michael Schaffer
  • Patent number: 11162100
    Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.
    Type: Grant
    Filed: January 6, 2020
    Date of Patent: November 2, 2021
    Assignees: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, INSTITUT NATIONAL DE LA SANTE DE LA RECHERCHE MEDICALE (INSERM), INSTITUT GUSTAVE-ROUSSY, UNIVERSITE DE VERSAILLES-ST QUENTIN EN YVELINES, UNIVERSITE PARIS-SUD
    Inventors: William Vainchenker, Valerie Ugo, Chloe James, Jean-Pierre Le Couedic, Nicole Casadevall
  • Patent number: 11142796
    Abstract: The disclosure provides methods for predicting and/or determining whether a subject has cancer based on the level of expression of miR-18b. The disclosure also provides methods for determining whether a cancer in a subject is progressing or regressing based upon the change of expression levels of miR-18b between two time points. The disclosure further provides methods to treat a subject with a cancer by administering a polynucleotide comprising miR-18b and/or an agent that enhances the expression of miR-18b.
    Type: Grant
    Filed: September 19, 2013
    Date of Patent: October 12, 2021
    Assignee: Sutter Bay Hospitals
    Inventors: Mohammed Kashani-Sabet, Altaf A. Dar
  • Patent number: 11111549
    Abstract: Disclosed are methods utilizing specific amplification of Candida sp. target nucleic acid for detecting the presence or absence of Candida sp. in a sample. Also disclosed are corresponding oligomers, including amplification oligomers, capture probes and detection probes, and combinations thereof, as well as corresponding reaction mixtures and kits.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: September 7, 2021
    Assignee: GEN-PROBE INCORPORATED
    Inventors: Angela S. Hudson, Damon K. Getman, Alice Jiang, Barbara L. Eaton
  • Patent number: 11098371
    Abstract: A kit for detecting urothelial carcinoma is provided. The kit includes at least one primer or probe for detecting one or more miRNAs, and the one or more miRNAs are selected from the group consisting of miR-19b-1, miR-636, miR-150, miR-155, miR-183, miR-378, miR-210, miR-487, and combinations thereof. A method for detecting urothelial carcinoma is also provided. The method includes detecting the expression level(s) of one or more miRNAs in a sample of a subject, and the one or more miRNAs are selected from the group consisting of miR-19b-1, miR-636, miR-150, miR-155, miR-183, miR-378, miR-210, miR-487, and combinations thereof.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: August 24, 2021
    Assignees: NATIONAL CENTRAL UNIVERSITY, DELTA ELECTRONICS. INC.
    Inventors: Nian-Han Ma, Chien-Lung Chen, Chen-Huan Lin, An-Lun Li, Chiu-Chin Huang, Chao-Hsiang Chang
  • Patent number: 10876163
    Abstract: The present invention relates to a method, in particular an in vitro method for identifying FoxP3-positive regulatory T cells, preferably CD25+CD4+ regulatory T cells of a mammal, comprising analysing the methylation status of at least one CpG position in the gene foxp3 or an orthologous or paralogous gene thereof, and the use of DNA-methylation analysis of the gene of the transcription factor FoxP3 for a detection and quality assurance and control of regulatory T cells. Furthermore, the present invention relates to a kit for performing the above methods as well as respective uses.
    Type: Grant
    Filed: February 28, 2007
    Date of Patent: December 29, 2020
    Assignees: Epiontis GmbH, Charite-Universitatsmedizin Berlin
    Inventors: Jochen Huehn, Stefan Floess, Alf Hamann, Sven Olek, Udo Baron
  • Patent number: 10793906
    Abstract: Biomarkers for identifying sepsis in humans are presented herein, as are related methods, uses, agents, and kits comprising same. Methods for treating, detecting, and diagnosing sepsis in humans are presented herein.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: October 6, 2020
    Assignee: CNA DIAGNOSTICS INC.
    Inventors: Christoph W. Sensen, Jung Soh, Petra Heidinger, Laura Villanova, Stefan Grabuschnig